FibroGen

Traded on the St. Petersburg Stock Exchange
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of therapeutics.
FibroGen stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

FibroGen balance sheet

Report period2018 2019 2020 2021 2022 Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

FibroGen cash flows

Report period2018 2019 2020 2021 2022 Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

FibroGen multipliers

Report period2018 2019 2020 2021 2022 Q2 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

FibroGen profitability

Report period2018 2019 2020 2021 2022 Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
FibroGen assets
FibroGen cash flows

FibroGen shares

TickerNameTypeNominal valueISINPrice
FGEN:USFibroGen, Inc.Common share-US31572Q8087$2.58
FibroGen news
10.05.2022
FibroGen's GAAP loss for 3 months of 2022 was $63.205 million, down 11.9% from $71.755 million in the prior year. Revenue increased by 58.3% to $60.827 million compared to $38.429 million a year earlier.
Source: {source} pictogram fibrogen.gcs-web.com
Pictogram next
01.03.2022
FibroGen's GAAP loss for 2021 was $290.023 million, up 53.2% from $189.291 million in the prior year. Revenue increased 33.5% to $235.309 million from $176.319 million a year earlier.
Source: {source} pictogram fibrogen.gcs-web.com
Pictogram next
10.11.2021
FibroGen reported a GAAP loss of $155.945 million for 9M 2021, up 19.4% from $130.657 million in the previous year. Revenues increased by 96.5% to $218.766 million from $111.32 million a year earlier.
Source: {source} pictogram fibrogen.gcs-web.com
Pictogram next
09.08.2021
FibroGen's GAAP loss for 6M 2021 was $206.066 million, up 25.9% from $163.661 million in the previous year. Revenue decreased 6.7% to $62.793 million from $67.288 million a year earlier.
Source: {source} pictogram fibrogen.gcs-web.com
Pictogram next
All FibroGen news
General information
Company nameFibroGen
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address409 ILLINOIS STREET SAN FRANCISCO CA 94158 415-978-1200
Mailing address409 ILLINOIS STREET SAN FRANCISCO CA 94158
Websitewww.fibrogen.com
Information disclosurewww.sec.gov